Current Challenges in Personalized Cancer Medicine
For this volume of Advances in Pharmacology we have brought together some of the foremost basic science and clinical researchers to discuss some of the new frontiers in the development of targeted cancer therapy. Although still in its formative stages, the development of targeted cancer therapies has already shown incredible promise in a limited number of cancer types. As basic cancer research and drug development continues, we expect this number to grow and more patients to benefit from these exciting advances. Through better patient selection and novel strategies to manage resistance, a future can be envisaged in which cancer can be reduced to the level of a chronic, manageable disease.
Audience
Pharmacologists, immunologists, and biochemists
Hardbound, 576 Pages
Published: September 2012
Imprint: Academic Press
ISBN: 978-0-12-397927-8
Contents
- Vertical pathway targeting in cancer therapy
- Histone Deacetylases (HDACs) as Mediators of Resistance to Apoptosis in Melanoma and as Targets for Combination Therapy with Selective BRAF Inhibitors
- Targeting the tumor stroma as a novel treatment strategy for breast cancer - shifting from the neoplastic cell-centric to a stroma-centric paradigm
- Targeting the Metabolic Microenvironment of Tumors
- Targeted Therapy for Matastasis
- Emerging Strategies for Targeting Cell Adhesion in Multiple Myeloma
- Targeting Notch Signaling for Cancer Therapeutic Intervention
- Stem-like cells and therapy resistance in squamous cell carcinomas
- Targeting the tumor stroma as a novel therapeutic approach for prostate cancer
- Resistance to chemotherapy: short-term drug tolerance and stem cell-like subpopulations
- Intratumoral Heterogeneity as a Therapy Resistance Mechanism: Role of Melanoma Subpopulations
- Chemoprevention of Melanoma
- Whole genome and exome sequencing of melanoma: a step toward personalised targeted therapy
- Targeted Therapy for Gastric Adenocarcinoma
- HSP90 Inhibitors for Cancer Therapy and Overcoming Drug Resistance
- Apoptosis in Targeted Therapy Responses: The Role of BIM
David Shahbazian, Joshua Sznol and Harriet M. Kluger Fritz Lai, Lei Jin, Stuart Gallagher, Branka Mijatov, Xu Dong Zhang and Peter Hersey Julia Tchou, Jose Conejo-Garcia Kate M. Bailey, Jonathan W. Wojtkowiak, Arig Ibrahim Hashim and Robert J. Gillies Michael A. Davies Rajesh R Nair, Anthony W Gebhard, Michael F Emmons and Lori A Hazlehurst Hongwei Shao, Qinghua Huang and Zhao-Jun Liu Nicole Facompre, Hiroshi Nakagawa and Meenhard Herlyn, Devraj Basu Omar E. Franco Kevin J. Basile and Andrew E. Aplin Rajasekharan Somasundaram, Jessie Villanueva and Meenhard Herlyn SubbaRao V. Madhunapantula and Gavin P. Robertson Ken Dutton-Regester and Nicholas K. Hayward Khaldoun Almhanna Komal Jhaveri and Shanu Modi Anthony C. Faber, Hiromichi Ebi, Carlotta Costa and Jeffrey A. Engelman
